[Late-onset neutropenia following ocrelizumab treatment in relapsing multiple sclerosis].

Abstract

We are reporting two cases of late-onset severe neutropenia following treatment with ocrelizumab in patients with relapsing multiple sclerosis. These cases highlight a rare but clinically significant side effect of a widely used multiple sclerosis treatment. This article aims to raise awareness among clinicians regarding this potential hematological complication, emphasizing the importance of vigilant monitoring and early intervention. Through these cases, we discuss the underlying pathophysiological mechanisms. Additionally, we wish to emphasize the importance of a multidisciplinary approach to manage this complication, involving close collaboration between neurologists, hematologists, and other specialists.